PCR AFTER NEOADJUVANT CHEMOTHERAPY AND SURVIVAL IN LOCALIZED BLADDER CANCER: A MOROCCAN EXPERIENCE

Background: Neoadjuvant cisplatin based chemotherapy followed by radical cystectomy is the standard of care for localized muscle invasive bladder cancer (MIBC). Pathological complete response (pCR) is a strong prognostic marker for survival. However, real world data from low and middle income countries remain limited. Objective: To evaluate operability and pCR rates after neoadjuvant chemotherapy and their correlation with overall survival (OS) and relapse free survival (RFS) in Moroccan patients with MIBC. Methods: We conducted a retrospective, single center study at the Medical Oncology Department of CHU Hassan II Fez, including 65 patients with MIBC who received at least 3 cycles of cisplatin based neoadjuvant chemotherapy between January 2018 and December 2023.